Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Thyroid Neoplasms 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Testicular Neoplasms 2Sarcoma 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Adrenal Gland Neoplasms 2Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Thymus Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solitary Fibrous Tumors 1Skin Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Penile Neoplasms 1Paraganglioma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Unknown Primary 1Neoplasm Metastasis 1

Interventions

lutetium Lu 177 dotatate 8lanreotide 4copper dotatate CU-64 4Octreotide 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4pasireotide 3Magnetic Resonance Spectroscopy 3Lutetium-177 3Lutetium 3gallium Ga 68 dotatate 2amino-acid, glucose, and electrolyte solution 2Temozolomide 2Nivolumab 2Irinotecan 2Ga(III)-DOTATOC 2Everolimus 2Etoposide 2Carboplatin 2zimberelimab 1regorafenib 1pembrolizumab 1irinotecan sucrosofate 1folfirinox 1famitinib 1cabozantinib 1arginyllysine 1abemaciclib 1X-Rays 1Sunitinib 1Somatostatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × NET × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡